This site is intended for U.S. healthcare professionals.
Menu
Close
Efficacy
Phase III Study Primary Endpoints
Success in ISGA: Clear or almost clear
Study Design
Phase III Study Secondary Endpoints
ISGA clear or almost clear
Time to ISGA success
Phase III Study: Other Endpoints
Pruritus
Quality of life assessments
Infant Study: Exploratory efficacy Endpoints
ISGA clear or almost clear
%BSA, EASI & POEM
Safety Data
Phase III Study Adverse Reactions*
Pivotal trial & 48-week extension study
Adverse Reactions
Open-Label Safety Extension Study*
Open-Label Safety Extension Study Rescue Therapy Endpoint
Study design
Infant Safety Study**
Adverse Reactions
Study design and Demographics
Savings & Support
Events
Materials
Videos
Copay Cards
Cost and Coverage
EUCRISA (n=1012) |
Vehicle (n=499) |
|
APPLICATION SITE PAIN1 |
4% (n=45) |
1% (n=6) |
|
APPLICATION SITE PAIN1 |
|
EUCRISA (n=1012) |
4% (n=45) |
Vehicle (n=499) |
1% (n=6) |
|
EUCRISA (n=517) | |
---|---|
APPLICATION SITE PAIN2 |
2% (n=12) |
APPLICATION SITE INFECTION2 |
1% (n=6) |
ATOPIC DERMATITIS2 |
3% (n=16) |
SAE=serious adverse event |
EUCRISA (n=517) | |
APPLICATION SITE PAIN2 |
2% (n=12) |
APPLICATION SITE INFECTION2 |
1% (n=6) |
ATOPIC DERMATITIS2 |
3% (n=16) |
SAE=serious adverse event |
Hear JP with mild-to-moderate AD explain what EUCRISA means to him and other babies like him
Not an actual patient
** This is an optional area where footnotes can live.
Read about rescue therapy in the 48 week Open-Label Safety Extension study
** This is an optional area where footnotes can live.
Find out more about the time to relief in pruritus as found in the Phase III study's exploratory endpoint
** This is an optional area where footnotes can live.
The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4
** This is an optional area where footnotes can live.
*Eligible patients pay as little as $10
Terms and Conditions apply
* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.
** This is an optional area where footnotes can live.
A savings and support program for your patients to help them with their access to EUCRISA
** This is an optional area where footnotes can live.
Register or sign in to check availability and request samples.
** This is an optional area where footnotes can live.
Contraindications
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
Adverse Reactions
The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.
Please see Full Prescribing Information and Patient Information
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.
Please see full Prescribing Information.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?